Aflibercept

Therapeutic Group

Ocular Vascular Disorder Agents

Indication Dosage

Neovascular (wet) Age-related Macular Degeneration: 

By Intravitreal Inj: 

  • Adult: Initially 2 Mg Once A Month For 3 Months, Then 2 Mg Every 2 Months, Review Treatment Frequency After 12 Months 

Macular Oedema Secondary To Retinal Vein Occlusion: 

By Intravitreal Inj: 

  • Adult: Initially 2 Mg Once A Month Until Maximum Visual Acuity Is Achieved Or There Are No Signs Of Disease Activity (discontinue Treatment If No Improvement In Visual And Anatomic Outcomes) 

Diabetic Macular Oedema: 

By Intravitreal Inj: 

  • Adult: Initially 2 Mg Once A Month For 5 Months, Then Maintenance 2 Mg Every 2 Months, Review Treatment Frequency After 12 Months (discontinue Treatment If No Improvement In Visual And Anatomic Outcomes) 

Myopic Choroidal Neovascularisation: 

By Intravitreal Inj: 

  • Adult: 2 Mg For 1 Dose, If Visual Or Anatomic Outcomes Indicate That Disease Persists, Additional Doses May Be Administered; The Interval Between 2 Doses Should Be Greater Than 1 Month

Content

  • Inj: Per ml: Aflibercet 40mg, Solution For Injection.

Pregnancy

Avoid Unless Potential Benefit Outweighs Risk

Stability

  • Vascular Endothelial Growth Factor Inhibitor

Contra Indications

  • Ocular Or Periocular Infection, Severe Intra-ocular Inflammation, Irreversible Ischaemic Visual Function Loss Cautions: Diabetic Patients With Uncontrolled Hypertension, Active Systemic Infection, Discontinue Treatment If Stage 3 Or 4 Macular Holes Develop Or In The Event Of A Retinal Break Or Rhegmatogenous Retinal Detachment (consult Product Literature For Full Details), Patients At Risk Of Retinal Pigment Epithelial Tear, Poorly Controlled Glaucoma.

Precautions

  • Ocular Or Periocular Infection, Severe Intra-ocular Inflammation, Irreversible Ischaemic Visual Function Loss Cautions: Diabetic Patients With Uncontrolled Hypertension, Active Systemic Infection, Discontinue Treatment If Stage 3 Or 4 Macular Holes Develop Or In The Event Of A Retinal Break Or Rhegmatogenous Retinal Detachment (consult Product Literature For Full Details), Patients At Risk Of Retinal Pigment Epithelial Tear, Poorly Controlled Glaucoma.

Lactation

  • Contraindicated, Discontinue Breast Feeding.

Side Effects

  • Cataract Formation
  • Corneal Abrasion
  • Oedema Or Haemorrhage
  • Conjunctival Hyperaemia
  • Eye Pain
  • Eyelid Oedema
  • Foreign Body Sensation In Eye
  • Increased Lacrimation
  • Injection-site Haemorrhage
  • Injection-site Pain
  • Ocular Hyperaemia
  • Punctate Keratitis
  • Raised Intra-ocular Pressure
  • Reduced Visual Acuity
  • Blurred Vision
  • Retinal Degeneration
  • Retinal Pigment Epithelium Detachment
  • Retinal Pigment Epithelium Tear
  • Vitreous Detachment
  • Vitreous Floaters
  • Vitreous Haemorrhage.
  • Rare: Hypopyon
  • Vitritis
  • Retinal Detachment
  • Retinal Tear
  • Uveitis

Available Brands